Kannalife Sciences, Inc.

About Kannalife Sciences, Inc.

Kannalife Sciences, Inc., a subsidiary of Neuropathix, Inc., is a biopharmaceutical company focused on researching and developing next-generation breakthrough therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain to address significant unmet medical needs.

Products & Services

Cannabinoid Therapeutics:Innovative CBD-like molecules designed for treating diseases such as Chemotherapy Induced Peripheral Neuropathy (CIPN), Hepatic Encephalopathy (HE), Mild Traumatic Brain Injury (mTBI), and chronic pain management.

KLS-13019:A patented CBD-like New Chemical Entity (NCE) with improved potency, bioavailability, safety, and effectiveness compared to CBD, aimed at treating various medical conditions.

Atopidine™:A therapeutic compound studied for its effects compared to CBD in UVB-radiation research.

Specialties

Cannabinoid Therapeutics Inflammation Treatment Neurodegeneration Oxidative Stress Neuropathic Pain Drug Development for Unmet Medical Needs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1493409 MR: - FA: $1.49 million USD FAN: 1493409	D: 2024-06-25 FD: 2024-06-25	1 investors

Grant Latest

2024-06-25

$1.5M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dean Petkanas

Chairman & CEO

W

William A. Kinney, PhD

Chief Scientific Officer

T

Thoma Kikis

Founder / Chief Communications Officer, Board Director

M

Mark Corrao

Chief Financial Officer

D

Douglas Brenneman, PhD

Chief Pharmacologist

M

Mark McDonnell, PhD

Chief Chemist

View 15 more team members with Pro

Unlock Full Team Directory

Recent News